STOCK TITAN

Illumina Expands Presence in Latin America

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced the creation of Illumina Colombia S.A.S. and Illumina México Productos de Biotecnología marking our commitment to expand genomics in Latin America and increase the level of support for our local customers and partners.

"Colombia is the second largest country by population in South America and México is one of Illumina's largest market for genomics in Latin America," said Nicole Berry, General Manager for the Americas at Illumina. "We have been investing in and growing and expanding our business in Latin America over the past few years. The time is right for us to increase our presence further in Colombia and México through the establishment of these local Illumina legal entities."

The entities will help advance Illumina's clinical business in Colombia and México, with a focus on key healthcare systems and hospitals. In addition, the entities will support local and nearby Illumina channel partners across Latin America, including countries in the Caribbean, Central America and South America. The entities will ensure Illumina's customers are able to keep their instruments functional and receive the very best training on the latest products.

Looking ahead, these new entities will work closer with Illumina customers and channel partners to execute key local partnership, not only in those countries, but throughout Latin America.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on TwitterFacebookLinkedInInstagram, and YouTube.

Investors:
Brian Blanchett
+1.858.291.6421
ir@illumina.com

Media:
Dr. Karen Birmingham
+1.646.355.2111
+44(0) 7500 105665
kbirmingham@illumina.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-expands-presence-in-latin-america-301388166.html

SOURCE Illumina, Inc.

Illumina Inc

NASDAQ:ILMN

ILMN Rankings

ILMN Latest News

ILMN Stock Data

18.78B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.